Oculis Holding AG (OCS) EBITDA (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly EBITDA of -$27.7 million for Q1 2026, down 24.89% year-over-year from -$36.9 million in Q1 2025, and down 7.48% quarter-over-quarter from -$25.8 million in Q4 2025.
Oculis Holding AG (OCS) EBITDA (2022 - 2026) Analysis & Trends
Oculis Holding AG's EBITDA history runs 5 years deep, the most recent figure standing at -$27.7 million for Q1 2026.
- In Q1 2026, EBITDA fell 24.89% year-over-year to -$27.7 million; the TTM figure through Mar 2026 stood at -$78.7 million (down 17.77% YoY), while the FY2025 annual figure was -$98.5 million, down 18.38% from the prior year.
- EBITDA for Q1 2026 stood at -$27.7 million, down from -$25.8 million in the prior quarter.
- The five-year high for EBITDA was -$20926.9 in Q3 2024, with the low at -$48.5 million in Q1 2023.
- The 5-year median for EBITDA is -$16.1 million (2024), against an average of -$17.5 million.
- Peak annual rise in EBITDA reached 99.86% in 2024, while the deepest fall reached 108.06% in 2024.
- Oculis Holding AG's EBITDA stood at -$11.5 million in 2022, then retreated by 19.07% to -$13.7 million in 2023, then tumbled by 43.44% to -$19.7 million in 2024, then sank by 31.02% to -$25.8 million in 2025, then slipped by 7.48% to -$27.7 million in 2026.
- Business Quant data shows OCS's EBITDA at -$27.7 million in Q1 2026, -$25.8 million in Q4 2025, and -$25372.2 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -11.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.76 Mn |
| Mar 31, 2026 | -27.75 Mn |
| Dec 31, 2025 | -25.82 Mn |
| Sep 30, 2025 | -25,372.22 |
| Jun 30, 2025 | -25.09 Mn |
| Mar 31, 2025 | -22.22 Mn |
| Dec 31, 2024 | -19.70 Mn |
| Sep 30, 2024 | -20,926.93 |
| Jun 30, 2024 | -24.86 Mn |
| Mar 31, 2024 | -17.56 Mn |
| Dec 31, 2023 | -13.74 Mn |
| Sep 30, 2023 | -14.67 Mn |
| Jun 30, 2023 | -11.95 Mn |
| Mar 31, 2023 | -48.46 Mn |
| Dec 31, 2022 | -11.54 Mn |
| Sep 30, 2022 | -7.12 Mn |
| Jun 30, 2022 | -9.59 Mn |